News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Allegro Diagnostics Enters License Agreement for Lung Cancer Molecular Testing Platform with Boston University and the University of Utah Foundation



6/29/2011 8:50:51 AM

MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics today announced that the company has entered into an exclusive license agreement with Boston University and the University of Utah Foundation for intellectual property related to the company’s molecular testing platform. This platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Financial terms of the agreement are undisclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES